ClinicalTrials.gg
TerminatedNCT03399435Updated Oct 11, 2018

A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade

A Phase 1 interventional study of Neosaxitoxin combined with bupivacaine low and epinephrine (T1) and Bupivacaine low combined with epinephrine (C1) in Anesthesia, Anesthesia, Local and Analgesia, sponsored by Grünenthal GmbH. Terminated at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-11.

Sponsored by Grünenthal GmbH · Phase 1, Interventional, and Other

How we know

Why this study was terminated
The sponsor decided to stop further dosing of healthy volunteers after reviewing the obtained efficacy data. The decision is not related to any safety concern.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Neosaxitoxin is a new compound that is in clinical development as local anesthetic for surgical anesthesia and postoperative analgesia.

The primary objective of this study is to evaluate the systemic and local safety and tolerability of ascending doses of neosaxitoxin alone and in combination with fixed doses of bupivacaine (with and without epinephrine), following brachial plexus blockade in healthy male subjects.

Secondary objectives:

  • Evaluate the pharmacodynamics (PD) of ascending doses of neosaxitoxin, alone and in combination with fixed doses of bupivacaine (with and without epinephrine), following brachial plexus blockade.
  • Characterize the pharmacokinetics (PK) of neosaxitoxin and bupivacaine after brachial plexus blockade with neosaxitoxin alone or different drug combinations: neosaxitoxin and epinephrine, neosaxitoxin and bupivacaine, or neosaxitoxin and bupivacaine and epinephrine.
02

Conditions studied

  • Anesthesia
  • Anesthesia, Local
  • Analgesia

Keywords

  • Regional anesthesia
  • Brachial plexus blockade
  • Sensory and motor function testing
03

In context

Lead sponsor

Grünenthal GmbH is the lead sponsor of 69 studies on the registry; 3 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has given written to participate.
  • Male subject, aged 18 years to 55 years, inclusive.
  • between 20.0 kg/m2 and 30.0 kg/m2 inclusive, with a minimal body weight of 60.0 kg.
  • Subject must be in good health as determined by the prior/concomitant diseases, physical and laboratory examinations.
  • Subject must be willing not to donate sperm and to use barrier (condom) during sexual intercourse with women from the administration of IMP until Day 90 since IMP administration. The subject must be willing to ensure that the female sexual partner of uses at least 1 additional method of contraception with a low failure rate defined as \<1% per year (e.g., oral contraceptives) during this time frame. A single barrier method alone is not acceptable.

Exclusion criteria

Exclusion Criteria:

At enrollment:

  • Resting pulse rate \<50 beats or >90 beats per minute.
  • Resting systolic blood pressure \<90 mmHg or >140 mmHg. Resting diastolic blood pressure >90 mmHg.
  • Prolongation of at enrollment, i.e., QTcF >450 ms, or presence of any other of risk factors for torsade de pointes or other disturbances of cardiac de- and repolarization.
  • Any out-of-reference range value for the following safety laboratory parameters: GGT, serum creatinine, PT, and .
  • Any exclusion range met for urinalysis and the following safety laboratory parameters: , AST, ALP, total , glucose, LDH, potassium, total protein, sodium, calcium, CK, , hematocrit, white blood cell count, and .
  • Any out-of-reference range value for any other safety laboratory parameter that is judged as by the investigator.
  • Positive or missing virus serology test for Type 1 or Type 2 antibodies and antigen, surface antigen, hepatitis B core antibodies, or virus antibodies.
  • Subject received IMP in another clinical trial within 1 month before the Enrollment Visit. Depending on the nature of the previous IMP, a longer washout may be needed.
  • Diseases or conditions known to interfere with the distribution, metabolism, or excretion of drugs.
  • History of orthostatic hypotension.
  • History of, or at risk of seizures.
  • Significant cardiovascular, respiratory, neuromuscular diseases, or other systemic illness.
  • Subject with an oxygen saturation of less than 95%, as measured by pulse oximetry, or subject with known or suspected respiratory difficulty or any condition that may compromise a subject's breathing or ability to maintain adequate oxygen saturation.
  • Known vocal chord palsy.
  • Any relevant symptom of neurological dysfunction of the motor and sensory system based on sensory and motor function testing. History or presence of symptoms of depression or anxiety disorders.
  • Previous injury or surgery of the involved shoulder in the last 2 years.
  • Any relevant local abnormality at the targeted area of injection.
  • Any acute or chronic pain condition requiring ongoing treatment or limiting daily activities.
  • Definite or suspected history of drug allergy, particularly to bupivacaine or other local anesthetics, epinephrine, or clinically relevant other allergies.
  • Evidence or history of alcohol or drug abuse including positive or missing drugs of abuse screen.
  • Regular use of any medication, including herbal remedies or over-the counter medication within 2 weeks before enrollment into this trial and anticipated use during the course of the trial.
  • Habitually smoking more than 10 cigarettes, 2 cigars, or 2 pipes of tobacco per day within the last 6 months before enrollment in this trial.
  • Known or suspected of not being able to comply with the requirements of the trial protocol or the instructions of the trial site staff.
  • Not able to communicate meaningfully with the trial site staff.
  • Employee of the investigator or trial site, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial site, as well as family members of the employees or the investigator.
  • Blood loss of 500 mL or more within 3 months before enrollment in this trial.

On Day -1:

  • Any relevant deterioration in the health of the subject since the Enrollment Visit possibly impacting participation in the trial, including AEs, safety laboratory parameters, vital signs, body temperature, , or other safety parameters at the discretion of the investigator.
  • Out-of-reference blood pressure or pulse rate if technical failure can be excluded and result is confirmed by at least 1 additional measurement: Systolic blood pressure \<90 mmHg or >140 mmHg, diastolic blood pressure >90 mmHg, pulse rate \<50 beats or >90 beats per minute.
  • Clinically relevant QTcF interval prolongation, i.e., QTcF interval >450 ms.
  • Any out-of-reference range value for the following safety laboratory parameters: GGT, serum creatinine, PT, and INR.
  • Any exclusion range met for urinalysis and the following safety laboratory parameters: ALT, AST, ALP, total bilirubin, glucose, LDH, potassium, total protein, sodium, calcium, CK, hemoglobin, hematocrit, white blood cell count, and platelets.
  • Any out-of-reference range value for any other safety laboratory parameter that is judged as clinically relevant by the investigator.
  • Positive or missing drugs of abuse screen.
  • Intake of forbidden medication since the enrollment in this trial.
  • Participation in another clinical trial since the Enrollment Visit.
  • Blood loss of 100 mL or more since enrollment in this trial.
  • Failure to comply with trial requirements, e.g., consumption of alcohol, etc., considered by the investigator to affect subject safety or interfere with the integrity of the trial.
  • Any relevant local abnormality at the targeted area of injection.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Part A

    8 cohorts are planned to be treated.

    Combination Product: Neosaxitoxin combined with bupivacaine low and epinephrine (T1) · Combination Product: Bupivacaine low combined with epinephrine (C1) · Combination Product: Bupivacaine high combined with epinephrine (C2)

  • Experimental
    Part B

    Part B will start at the earliest after 4 cohorts of Part A have been treated. Up to 8 cohorts are planned to be treated.

    Combination Product: Neosaxitoxin combined with bupivacaine low (T2) · Drug: Bupivacaine low (C3) · Drug: Bupivacaine high (C4)

  • Experimental
    Part C

    Part C will comprise 4 treatment groups. The neosaxitoxin dose will be the same in all 4 treatment groups.

    Drug: Neosaxitoxin (T3) · Combination Product: Neosaxitoxin combined with epinephrine (T4) · Combination Product: Neosaxitoxin combined with bupivacaine low and epinephrine · Combination Product: Neosaxitoxin combined with bupivacaine low

Interventions

  • Combination productNeosaxitoxin combined with bupivacaine low and epinephrine (T1)

    A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.

  • Combination productBupivacaine low combined with epinephrine (C1)

    A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.

  • Combination productBupivacaine high combined with epinephrine (C2)

    A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.

  • Combination productNeosaxitoxin combined with bupivacaine low (T2)

    A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.

  • DrugBupivacaine low (C3)

    A single injection: Bupivacaine from 10 to 80 mg.

  • DrugBupivacaine high (C4)

    A single injection: Bupivacaine 100 mg.

  • DrugNeosaxitoxinStudies of NeosaxitoxinNeosaxitoxin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single injection: Neosaxitoxin will be between 1.25 and 60 µg.

  • Combination productNeosaxitoxin combined with epinephrine (T4)

    Drug pages: NeosaxitoxinStudies of NeosaxitoxinNeosaxitoxin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EpinephrineStudies of EpinephrineEpinephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.

  • Combination productNeosaxitoxin combined with bupivacaine low and epinephrine

    A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.

  • Combination productNeosaxitoxin combined with bupivacaine low

    A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).

06

What researchers measure

Primary outcomes

  1. Occurrence of dose limiting events (DLEs) in all parts of the trial.

    Time frame: up to 15 days after IMP (investigational medicinal product, i.e. study drug administration)

  2. Occurrence of other adverse events (AEs) leading to premature termination of dose escalation in Part A and Part B.

    Time frame: up to 15 days after IMP administration

Secondary outcomes

  1. Cold detection threshold (CDT).

    Time frame: Baseline, 24 and 48 hours after IMP administration

  2. Warm detection threshold (WDT)

    Time frame: Baseline, 24 and 48 hours after IMP administration

  3. Mechanical detection threshold (MDT)

    Time frame: Baseline, 24 and 48 hours after IMP administration

  4. Cold pain threshold (CPT)

    Time frame: Baseline, 24 and 48 hours after IMP administration

  5. Heat pain threshold (HPT)

    Time frame: Baseline, 24 and 48 hours after IMP administration

  6. Mechanical pain threshold (MPT)

    Time frame: Baseline, 24 and 48 hours after IMP administration

  7. Muscle grip strength (ipsilateral)

    Time frame: Baseline, 24 and 48 hours after IMP administration

  8. Muscle motor function (flexion and extension elbow joint, abduction shoulder joint)

    Time frame: Baseline, 24 and 48 hours after IMP administration

  9. AUC0-t of neosaxitoxin

    Time frame: up to 56 hours after IMP administration

  10. AUC0-t of bupivacaine

    Time frame: up to 56 hours after IMP administration

  11. Cmax of neosaxitoxin

    Time frame: up to 56 hours after IMP administration

  12. Cmax of bupivacaine

    Time frame: up to 56 hours after IMP administration

  13. tmax of neosaxitoxin

    Time frame: up to 56 hours after IMP administration

  14. tmax of bupivacaine

    Time frame: up to 56 hours after IMP administration

07

Study locations

1 site
  • NL001
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — Information available on the Grünenthal Group Web Site ( according to the EFPIA Data Sharing Principles.

Data sharing details ↗ · www.grunenthal.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Sep 2018, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 16, 2018
StartActual
Jan 30, 2018
Primary completionActual
Sep 21, 2018
CompletionActual
Sep 21, 2018
Last update
Oct 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03399435
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Jan 16, 2018
Start date
Jan 30, 2018
Primary completion
Sep 21, 2018
Completion
Sep 21, 2018
Last update
Oct 11, 2018

Study contacts

Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neosaxitoxin

Start the discussion